Sara Araújo, Ana Paula Neto, Maria João Pinho, Sofia Dória, Alberto Barros, Filipa Carvalho
{"title":"对卵母细胞捐献候选人进行基因研究。","authors":"Sara Araújo, Ana Paula Neto, Maria João Pinho, Sofia Dória, Alberto Barros, Filipa Carvalho","doi":"10.5935/1518-0557.20240087","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>There is a rising demand for assisted reproductive medicine, including sperm, oocyte and embryo donation. Besides medical and legal considerations, genetic testing, including carrier screening for multiple autosomal and X-linked recessive disorders plays an essential role in evaluating hereditary risk among donors and therefore exclude them from the donation process.</p><p><strong>Methods: </strong>A retrospective study was conducted on oocyte donors from a private clinic of assisted reproduction who underwent genetic testing between June 2014 and September 2023. Pre and post-test procedures were performed at the private clinic while karyotyping and carrier screening for Cystic Fibrosis, Fragile X syndrome and Spinal Muscular Atrophy were performed at the Genetic Unit of Faculty of Medicine, University of Porto.</p><p><strong>Results: </strong>Among 581 donors, 81 women were excluded from the donation process since 5/563 had an alteration in karyotype, 57/581 were carriers of a Cystic Fibrosis Transmembrane conductance Regulator pathogenic variant or had a 5T allele, 11/394 had Survival of Motor Neuron 1 deletion and 8/426 had an intermediate or premutation allele in Fragile X Messenger Ribonucleoprotein gene. While recommendations from fertility societies advocate for comprehensive screening, opinions differ on the mandatory implementation of expanded carrier screening.</p><p><strong>Conclusions: </strong>In conclusion, the genetic tests and the pre and post-test counseling is imperative to optimize reproductive outcomes in the oocyte donation process.</p>","PeriodicalId":46364,"journal":{"name":"Jornal Brasileiro de Reproducao Assistida","volume":" ","pages":"61-66"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867239/pdf/","citationCount":"0","resultStr":"{\"title\":\"Genetic study on candidates for oocyte donation.\",\"authors\":\"Sara Araújo, Ana Paula Neto, Maria João Pinho, Sofia Dória, Alberto Barros, Filipa Carvalho\",\"doi\":\"10.5935/1518-0557.20240087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>There is a rising demand for assisted reproductive medicine, including sperm, oocyte and embryo donation. Besides medical and legal considerations, genetic testing, including carrier screening for multiple autosomal and X-linked recessive disorders plays an essential role in evaluating hereditary risk among donors and therefore exclude them from the donation process.</p><p><strong>Methods: </strong>A retrospective study was conducted on oocyte donors from a private clinic of assisted reproduction who underwent genetic testing between June 2014 and September 2023. Pre and post-test procedures were performed at the private clinic while karyotyping and carrier screening for Cystic Fibrosis, Fragile X syndrome and Spinal Muscular Atrophy were performed at the Genetic Unit of Faculty of Medicine, University of Porto.</p><p><strong>Results: </strong>Among 581 donors, 81 women were excluded from the donation process since 5/563 had an alteration in karyotype, 57/581 were carriers of a Cystic Fibrosis Transmembrane conductance Regulator pathogenic variant or had a 5T allele, 11/394 had Survival of Motor Neuron 1 deletion and 8/426 had an intermediate or premutation allele in Fragile X Messenger Ribonucleoprotein gene. While recommendations from fertility societies advocate for comprehensive screening, opinions differ on the mandatory implementation of expanded carrier screening.</p><p><strong>Conclusions: </strong>In conclusion, the genetic tests and the pre and post-test counseling is imperative to optimize reproductive outcomes in the oocyte donation process.</p>\",\"PeriodicalId\":46364,\"journal\":{\"name\":\"Jornal Brasileiro de Reproducao Assistida\",\"volume\":\" \",\"pages\":\"61-66\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867239/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jornal Brasileiro de Reproducao Assistida\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5935/1518-0557.20240087\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jornal Brasileiro de Reproducao Assistida","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5935/1518-0557.20240087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:对辅助生殖医学,包括精子、卵细胞和胚胎捐献的需求日益增长。除了医疗和法律方面的考虑外,基因检测,包括多种常染色体和 X 连锁隐性遗传疾病的携带者筛查,在评估捐献者的遗传风险方面起着至关重要的作用,从而将他们排除在捐献过程之外:对一家私人辅助生殖诊所的卵细胞捐献者进行了一项回顾性研究,这些捐献者在 2014 年 6 月至 2023 年 9 月期间接受了基因检测。检测前和检测后的程序在该私人诊所进行,而囊肿性纤维化、脆性 X 综合征和脊髓性肌肉萎缩症的核型分析和携带者筛查则在波尔图大学医学院遗传学组进行:结果:在 581 名捐献者中,有 81 名妇女被排除在捐献过程之外,因为其中 5/563 人的核型发生了改变,57/581 人是囊性纤维化跨膜传导调节器致病变异或 5T 等位基因的携带者,11/394 人是运动神经元 1 缺失的存活者,8/426 人是脆性 X 信使核糖核蛋白基因的中间等位基因或突变前等位基因的携带者。虽然生育协会的建议主张进行全面筛查,但对于是否强制实施扩大的携带者筛查却存在不同意见:总之,要优化卵细胞捐献过程中的生殖结果,基因检测和检测前后的咨询必不可少。
Objective: There is a rising demand for assisted reproductive medicine, including sperm, oocyte and embryo donation. Besides medical and legal considerations, genetic testing, including carrier screening for multiple autosomal and X-linked recessive disorders plays an essential role in evaluating hereditary risk among donors and therefore exclude them from the donation process.
Methods: A retrospective study was conducted on oocyte donors from a private clinic of assisted reproduction who underwent genetic testing between June 2014 and September 2023. Pre and post-test procedures were performed at the private clinic while karyotyping and carrier screening for Cystic Fibrosis, Fragile X syndrome and Spinal Muscular Atrophy were performed at the Genetic Unit of Faculty of Medicine, University of Porto.
Results: Among 581 donors, 81 women were excluded from the donation process since 5/563 had an alteration in karyotype, 57/581 were carriers of a Cystic Fibrosis Transmembrane conductance Regulator pathogenic variant or had a 5T allele, 11/394 had Survival of Motor Neuron 1 deletion and 8/426 had an intermediate or premutation allele in Fragile X Messenger Ribonucleoprotein gene. While recommendations from fertility societies advocate for comprehensive screening, opinions differ on the mandatory implementation of expanded carrier screening.
Conclusions: In conclusion, the genetic tests and the pre and post-test counseling is imperative to optimize reproductive outcomes in the oocyte donation process.